Diabetes and Immune Checkpoint Inhibitors-Response

Clin Cancer Res. 2023 Oct 2;29(19):4017-4018. doi: 10.1158/1078-0432.CCR-23-2097.

Authors

Alessio Cortellini^{1

2}, Antonio D'Alessio^{2

3}, David J Pinato^{2

3}

Affiliations

¹ Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, Roma, Italy.
² Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom.
³ Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

PMID: 37779446
DOI: 10.1158/1078-0432.CCR-23-2097

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Letter
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use
Diabetes Mellitus*
Humans
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy
Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors
Antibodies, Monoclonal

Grants and funding